TRACE project deliverables
The page lists 7 deliverables related to the research project "TRACE".
List of Deliverables
| title and desprition | type | last update |
|---|---|---|
Individualized press release for every partnerPatient organisations will be included in a three level approach. Patient organisations will be involved in dissemination (local level), a representative of the national umbrella organisation will be Programme: H2020-EU.3.1.3. - Topic(s): SC1-PM-08-2017 |
Documents, reports | 2020-04-07 |
Registration number of clinical study in a WHO- or ICMJE-approved registryThe clinical trial documents will be submitted to the competent authorities and the ethical review boards. The partners LMU, OPBG, LUMC, CHU, UNEW, UZG are involved in this task. The task leader LMU will submit the trial to the German competent authority Paul-Ehrlich-Institut. The role of all other participants (OPBG, LUMC, CHU, UNEW, UZG) will be to submit the trial to their national and local authorities. Programme: H2020-EU.3.1.3. - Topic(s): SC1-PM-08-2017 |
Documents, reports | 2020-04-07 |
Final version of study protocol as approved by first regulatory/ethics committee (Package 1)The clinical trial documents will be submitted to the competent authorities and the ethical review boards. The partners LMU, OPBG, LUMC, CHU, UNEW, UZG are involved in this task. The task leader LMU will submit the trial to the German competent authority Paul-Ehrlich-Institut. The role of all other participants (OPBG, LUMC, CHU, UNEW, UZG) will be to submit the trial to their national and local authorities. Deliverables D 2.5 and 2.6 are the outcome of this task, which will contain the whole submission package, including the final version of the study protocol as approved by competent authorities. Programme: H2020-EU.3.1.3. - Topic(s): SC1-PM-08-2017 |
Documents, reports | 2020-04-07 |
Launch of website and social media accountLMU will set up and perform maintenance of the consortium homepage and social media accounts such as LinkedIn, Facebook or Twitter dependent on the preference of patient organisations. All participants of the consortium will provide information for the website. Programme: H2020-EU.3.1.3. - Topic(s): SC1-PM-08-2017 |
Websites, patent fillings, videos etc. | 2020-04-07 |
Plan for the analysis of the functional activity of the multivirus-specific T cell productTherefore, the functional activity of T cells specific for immunodominant epitopes derived from different proteins of the targeted viruses (e.g. CMV, EBV, and AdV) presented by different HLA alleles will be determined. On target (anti-viral) reactivity of the isolated T-cell products will Programme: H2020-EU.3.1.3. - Topic(s): SC1-PM-08-2017 |
Documents, reports | 2020-04-07 |
SOP for immune monitoring of patient samplesimmune monitoring of peripheral blood and bone marrow samples taken from the patients enrolled in the clinical trial described in this proposal are of utmost importance. Blood samples and if possible bone marrow samples will be drawn from the patients before the infusion of the multivirus- Programme: H2020-EU.3.1.3. - Topic(s): SC1-PM-08-2017 |
Documents, reports | 2020-04-07 |
Site selectionSite feasibility assessment and final site selection and contracts are needed for approximately 20-25 sites (3rd party as subcontractors). LMU will coordinate the site selection and will set up a contact office for all clinical and regulatory questions raised by physicians that treat patients or may have candidates for an inclusion into this clinical trial. LMU, OPBG, LUMC, CHU, UNEW and UZG will select the clinical sites for recruitment of patients in their Country. Programme: H2020-EU.3.1.3. - Topic(s): SC1-PM-08-2017 |
Documents, reports | 2020-04-07 |